|
||
|
|
|
||
|
|
In contrast to the previous Figure, this Figure shows the subsets of major bleeding. For the 2 critical subsets, bleeding into a critical organ and fatal bleeding (light blue highlight in the Figure), both of these were lower in the rivaroxaban arm than in the warfarin arm.[112][116] These are similar to the data with dabigatran in RE-LY, except that the benefit for fatal bleeding with rivaroxaban is even more dramatic. The reduction in “bleeding into a critical organ” refers primarily to intracranial bleeding, and here again the reduction seen with rivaroxaban is similar to that seen with dabigatran. Indeed, a lower likelihood of bleeding into the head seems to be feature with the NOACs.
Reiffel JA. Am J Med 2013; 126: 00-00.
[112] Xarelto® (rivaroxaban) film-coated oral tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011. Revised: November 2012.
[116] Supplementary appendix to: Patel MR, Mahaffey KW, Garg J, et al; the ROCKET AF Steering Committee, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. http://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_appendix.pdf